Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of VSA003 in Healthy Chinese Adults
NCT05851066Phase 1Completed
- Sponsor
- Visirna Therapeutics
- Start
- Jun 2023
- Primary completion
- May 2024
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zodasiran in dyslipidemia, familial hypercholesterolemia (FH) and hypertriglyceridemia (4 arms), sponsored by Visirna Therapeutics. Primary endpoint: Frequency and severity of adverse event (AE) and serious adverse event (SAE). Started Jun 2023; status: completed.
02
Drugs
zodasiran
03
Conditions
dyslipidemiafamilial hypercholesterolemia (FH)hypertriglyceridemia
Beyond the preview
Go deeper on NCT05851066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851066.